This article has been updated to include comments from Vermillion that the company is evaluating options for additional sources of funding.

Originally published May 25.

Vermillion just launched its OVA1 ovarian tumor triage test in March, but it may need to launch additional tests if it is to climb out of the red.

According to quarterly results filed with the US Securities and Exchange Commission on May 24, Vermillion said it had accumulated a deficit of $291 million from its inception in 1993 through March 31, 2010.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.